<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cardiovascular effects of hyperthyroidism</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cardiovascular effects of hyperthyroidism</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cardiovascular effects of hyperthyroidism</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Irwin Klein, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thyroid hormone has important effects on cardiac muscle, the peripheral circulation, and the sympathetic nervous system that alter cardiovascular hemodynamics in a predictable way in patients with hyperthyroidism. The main changes are [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increases in heart rate, cardiac contractility, systolic and mean pulmonary artery pressure, cardiac output, diastolic relaxation, and myocardial oxygen consumption</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reductions in systemic vascular resistance and diastolic pressure</p><p></p><p>The major cardiovascular manifestations of hyperthyroidism will be reviewed here. Other symptoms associated with this disorder are discussed separately. (See  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The cellular actions of thyroid hormone are mediated by the binding of triiodothyronine (T3) to nuclear receptors. It is T3 and not thyroxine (T4) that is transported into the cardiac myocyte. The subsequent binding of the T3-receptor complexes to DNA regulates the expression of genes, specifically those regulating calcium cycling in the cardiac myocyte [<a href="#rid1">1,2</a>]. T3 may also have non-nuclear actions through mechanisms not yet fully understood [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Adrenergic effects</span><span class="headingEndMark"> — </span>Some actions of T3 on the heart produce clinical findings similar to those of beta-adrenergic stimulation [<a href="#rid4">4</a>]. The interaction between T3 and the adrenergic nervous system is best exemplified by the ability of essentially all beta blockers to alleviate many of the symptoms of hyperthyroidism (see  <a class="medical medical_review" href="/d/html/7874.html" rel="external">"Beta blockers in the treatment of hyperthyroidism"</a>). This may involve increased beta-adrenergic receptor density, increased expression of the stimulatory guanine nucleotide-binding protein (G protein), and downregulation of the cardiac-specific isoform of the adenylyl cyclase catalytic subunit [<a href="#rid5">5-7</a>]. Whether humans with hyperthyroidism have increased sensitivity to catecholamines is uncertain, but it seems clear that T3 effects on the heart can occur independently of beta-adrenergic receptor stimulation [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Chronotropic and inotropic stimulation</span><span class="headingEndMark"> — </span>Hyperthyroidism predictably increases heart rate and cardiac contractility [<a href="#rid6">6,8</a>]. Virtually all measures of cardiac function (including left ventricular ejection fraction [LVEF], the rate of ventricular pressure development, diastolic relaxation, and cardiac output) are increased [<a href="#rid1">1</a>]. As a result, cardiac output increases by as much as 250 percent and pulse pressure widens (<a class="graphic graphic_figure graphicRef85918" href="/d/graphic/85918.html" rel="external">figure 1</a>). These functional changes are most likely the result of an increase in expression of myocardial sarcoplasmic reticulum calcium-dependent adenosine triphosphatase, a decrease in the expression of its inhibitor, phospholamban, and a decline in systemic vascular resistance [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Cardiovascular symptoms and signs are common in patients with hyperthyroidism [<a href="#rid9">9</a>], and in some patients, these symptoms predominate (<a class="graphic graphic_table graphicRef56219" href="/d/graphic/56219.html" rel="external">table 1</a>). They include:</p><p class="bulletIndent1"><span class="glyph">●</span>Tachycardia, at rest, during sleep, and exaggerated during exercise.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Palpitations, due to both tachycardia and more forceful cardiac contractility.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperdynamic precordium, indicative of the increase in cardiac contractility and cardiac workload.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systolic hypertension with widened pulse pressure [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Exertional dyspnea, which is more due to respiratory and skeletal muscle weakness than cardiac dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angina-like chest pain, with electrocardiogram (ECG) changes suggesting myocardial ischemia, which can occur especially in women; this appears to be the result of coronary vasospasm [<a href="#rid11">11</a>] and responds to treatment with orally administered calcium channel blockers and rendering the patients euthyroid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increase in left ventricular (LV) mass index and LV hypertrophy [<a href="#rid12">12,13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased ventricular irritability, especially in amiodarone-treated patients with a prior history of ventricular ectopy (often in the setting of implanted cardiac defibrillators) [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased clearance of coagulation factors, leading to an increase in sensitivity to <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> anticoagulation [<a href="#rid15">15,16</a>].</p><p></p><p>Hyperthyroidism is also associated with an increased risk of atrial fibrillation, heart failure, pulmonary hypertension, and angina, as described in the following sections.</p><p class="headingAnchor" id="H6"><span class="h2">Atrial fibrillation</span><span class="headingEndMark"> — </span>Hyperthyroid patients with normal hearts have more premature supraventricular depolarizations, premature atrial complex (PAC; also referred to a premature atrial beat, premature supraventricular complex, or premature supraventricular beat), more nonsustained supraventricular tachycardias, increased heart rate, and reduced heart rate variability [<a href="#rid17">17</a>]. The latter is primarily the result of decreased parasympathetic tone. These electrical triggers may contribute to paroxysmal atrial tachycardia, atrial fibrillation, and atrial flutter. Among these arrhythmias, atrial fibrillation is the most common, occurring in 5 to 15 percent of patients, especially patients ≥60 years of age [<a href="#rid6">6,18,19</a>]. In a population-based study of 40,628 patients with clinical hyperthyroidism, 8.3 percent had atrial fibrillation or flutter [<a href="#rid18">18</a>]. Factors associated with increased risk included male sex, increasing age, coronary heart disease, heart failure, and valvular heart disease [<a href="#rid4">4</a>]. The association with increasing age presumably reflects the age-related reduction in the threshold for developing atrial fibrillation.</p><p>Complications of atrial fibrillation in patients with hyperthyroidism include heart failure and thromboembolism, although it remains controversial whether atrial fibrillation in hyperthyroidism is associated with a higher thromboembolic risk than atrial fibrillation in other settings [<a href="#rid1">1,6,19</a>] (see  <a class="medical medical_review" href="/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>). Patients with overt thyrotoxicosis, especially females of East Asian descent (eg, Japanese, Chinese, and Korean), may present with focal neurologic findings, falsely suggesting central nervous system embolic events when indeed it is the result of central arterial vasospasm (moyamoya disease) [<a href="#rid4">4,20,21</a>]. (See <a class="local">'Stroke'</a> below.)</p><p>Approximately 55 to 75 percent of patients with atrial fibrillation due to hyperthyroidism and no other underlying cardiac valvular disease will return to sinus rhythm within three to six months after treatment of the thyrotoxic state [<a href="#rid1">1</a>]. In patients with persistent atrial fibrillation, the question of additional forms of therapy needs to be addressed. (See  <a class="medical medical_review" href="/d/html/1045.html" rel="external">"Management of atrial fibrillation: Rhythm control versus rate control"</a>.)</p><p>The other atrial arrhythmias associated with hyperthyroidism are most likely to be detected by monitoring, because they do not often cause symptoms. The risk of ventricular arrhythmias in the non-ischemic (normal) heart is not increased [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Heart failure</span><span class="headingEndMark"> — </span>Heart failure is most commonly seen as a result of longstanding, often untreated disease with coexistent atrial fibrillation. In one study, only 6 percent of hyperthyroid patients had heart failure, average age was 66 years; 94 percent had coexistent atrial fibrillation and 47 percent had LV systolic dysfunction [<a href="#rid22">22</a>]. In others, it is a complication of prolonged marked sinus tachycardia. The signs and symptoms of heart failure almost always resolve when the ventricular rate is slowed, normal sinus rhythm is restored, and the patients are rendered euthyroid [<a href="#rid4">4,5,22</a>].</p><p>In one study, half had LV systolic dysfunction with LV ejection fraction &lt;50 percent, and 85 percent had resolution of LV dysfunction after attaining euthyroidism [<a href="#rid22">22</a>].</p><p>Heart failure in the absence of underlying cardiac disease or arrhythmia is thought to reflect a rate-related cardiomyopathy, which disappears when the hyperthyroidism is treated. There is no clear histopathologic correlate of this cardiomyopathy, and treatment is primarily directed at rate control with beta-adrenergic blockade [<a href="#rid5">5</a>]. Pulmonary hypertension can also produce signs of isolated right heart failure with a rise in central venous pressure, neck vein distension, and hepatic congestion [<a href="#rid4">4,23</a>]. (See <a class="local">'Pulmonary hypertension'</a> below and  <a class="medical medical_review" href="/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy"</a>.)</p><p>Hyperthyroidism is associated with an increase in N-terminal pro-B natriuretic peptide (NT-proBNP) in hyperthyroid patients without cardiac insufficiency [<a href="#rid24">24</a>]. NT-proBNP was positively correlated with LV end-diastolic diameter and interventricular septal thickness, and negatively correlated with LV ejection fraction [<a href="#rid24">24</a>]. Mild iatrogenic hyperthyroidism is also associated with an increase in NT-proBNP, without a measurable increase in systolic blood pressure or pulse pressure [<a href="#rid24">24</a>]. This may reflect the increased atrial size which results from increased renal sodium reabsorption, plasma volume, or pulmonary hypertension [<a href="#rid25">25</a>].</p><p>Tricuspid and/or mitral regurgitation have also been described in patients with hyperthyroidism of all causes [<a href="#rid26">26-28</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Pulmonary hypertension</span><span class="headingEndMark"> — </span>Pulmonary hypertension has been reported with increasing frequency in patients with overt hyperthyroidism. Pulmonary artery pressures average twice normal values (10 mmHg) and may be as high as 30 to 50 mmHg. These changes reverse with treatment of the hyperthyroidism and may reflect the increase in cardiac output without the concomitant decline in pulmonary vascular resistance observed in the systemic circulation [<a href="#rid26">26-28</a>]. (See  <a class="medical medical_review" href="/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Angina pectoris</span><span class="headingEndMark"> — </span>Patients with angina may have chest pain more often when they become hyperthyroid, presumably because of the increase in cardiac oxygen consumption, due either to a direct effect of triiodothyronine (T3) on cardiac muscle or to an increase in peripheral oxygen demand. In the young patient with normal coronary anatomy, this may be due to coronary vasospasm (Prinzmetal angina).</p><p>Other patients first develop angina when they become hyperthyroid. In a hospital-based study of 1049 patients who were admitted emergently, 6 percent had high serum T3 concentrations at the time of admission; these patients had a 2.6-fold higher risk of having angina pectoris or a myocardial infarction at that time, as compared with those patients with normal serum T3 concentrations [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Stroke</span><span class="headingEndMark"> — </span>Ischemic cerebrovascular disease is a rare complication of hyperthyroidism. In addition, neurologic findings similar to that seen in moyamoya disease have been described in several patients with Graves' disease (especially those of East Asian descent [eg, Japanese, Chinese, Korean]) and may simulate the clinical findings of embolic disease. It is important to distinguish these two entities since the treatment is different. (See  <a class="medical medical_review" href="/d/html/4836.html" rel="external">"Neurologic manifestations of hyperthyroidism and Graves' disease"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">SUBCLINICAL HYPERTHYROIDISM</span><span class="headingEndMark"> — </span>Patients with subclinical hyperthyroidism (normal serum thyroid hormone and low serum thyroid-stimulating hormone [TSH] concentrations) have more subtle cardiac findings. These include increases in heart rate and cardiac contractility and modest degrees of cardiac hypertrophy and, at least in older adults, an increase in risk of atrial fibrillation as compared with euthyroid subjects (<a class="graphic graphic_figure graphicRef55024" href="/d/graphic/55024.html" rel="external">figure 2</a>). Subclinical hyperthyroidism is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults", section on 'Cardiovascular effects'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The cardiovascular manifestations of hyperthyroidism are best corrected by treating the hyperthyroidism, whether with radioiodine or an antithyroid drug. (See  <a class="medical medical_review" href="/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment"</a> and  <a class="medical medical_review" href="/d/html/7873.html" rel="external">"Treatment of toxic adenoma and toxic multinodular goiter"</a> and  <a class="medical medical_review" href="/d/html/7879.html" rel="external">"Radioiodine in the treatment of hyperthyroidism"</a> and  <a class="medical medical_review" href="/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease"</a>.)</p><p>Beta blockers, such as <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> or <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a>, are also useful in relieving palpitations and in slowing the heart rate in patients with sinus tachycardia [<a href="#rid30">30</a>] (see  <a class="medical medical_review" href="/d/html/7874.html" rel="external">"Beta blockers in the treatment of hyperthyroidism"</a>). It is important to recognize that while calcium channel blockers of all types are commonly used in the acute treatment of atrial fibrillation, the intravenous use of these agents pose a potential risk in patients with underlying thyrotoxicosis. The vasodilatory and negative inotropic properties of these drugs can lead to hypotension and cardiovascular collapse [<a href="#rid31">31,32</a>].</p><p>Additional measures may be needed in patients with atrial fibrillation, marked palpitations, or severe tachycardia [<a href="#rid1">1,5,33</a>]. The management of atrial fibrillation is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>.)</p><p>Among patients with overt heart failure, standard therapy should be given if the patient is older, known or suspected to have preexisting heart disease or hypertension, or the heart failure does not improve when the heart rate is slowed (see  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'</a>). In certain circumstances, especially with severe hyperthyroidism or thyroid storm, intensive cardiovascular monitoring and treatment of other comorbid conditions (infection, trauma, acute psychiatric illness) is required [<a href="#rid4">4,6</a>]. (See  <a class="medical medical_review" href="/d/html/7885.html" rel="external">"Thyroid storm"</a>.)</p><p class="headingAnchor" id="H3253683"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular hemodynamics</strong> – Thyroid hormone has important effects on cardiac muscle, the peripheral circulation, and the sympathetic nervous system. Some actions of triiodothyronine (T3) on the heart produce clinical findings similar to those of beta-adrenergic stimulation. Hyperthyroidism predictably increases heart rate and cardiac contractility. Virtually all measures of cardiac function (including left ventricular ejection fraction [LVEF], the rate of ventricular pressure development, diastolic relaxation, and cardiac output) are increased (<a class="graphic graphic_table graphicRef56219" href="/d/graphic/56219.html" rel="external">table 1</a>). (See <a class="local">'Chronotropic and inotropic stimulation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac clinical manifestations</strong> – Hyperthyroidism is also associated with an increased risk of atrial fibrillation, heart failure, pulmonary hypertension, and angina-like symptoms. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of cardiovascular manifestations</strong> – The cardiovascular manifestations of hyperthyroidism are best corrected by treating the hyperthyroidism, whether with radioiodine or an antithyroid drug. Beta blockers, such as <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> or <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a>, are also useful in relieving palpitations and in slowing the heart rate in patients with sinus tachycardia. (See <a class="local">'Treatment'</a> above and  <a class="medical medical_review" href="/d/html/7879.html" rel="external">"Radioiodine in the treatment of hyperthyroidism"</a> and  <a class="medical medical_review" href="/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease"</a> and  <a class="medical medical_review" href="/d/html/7874.html" rel="external">"Beta blockers in the treatment of hyperthyroidism"</a>.)</p><p></p><p class="bulletIndent1">Additional measures may be needed in patients with atrial fibrillation, marked palpitations, severe tachycardia, or heart failure. In certain circumstances, especially with severe hyperthyroidism or thyroid storm, intensive cardiovascular monitoring and treatment of other comorbid conditions (infection, trauma, acute psychiatric illness) is required. (See  <a class="medical medical_review" href="/d/html/7885.html" rel="external">"Thyroid storm"</a> and  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'</a> and  <a class="medical medical_review" href="/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344:501.</a></li><li><a class="nounderline abstract_t">Brent GA. The molecular basis of thyroid hormone action. N Engl J Med 1994; 331:847.</a></li><li><a class="nounderline abstract_t">Davis PJ, Davis FB. Nongenomic actions of thyroid hormone on the heart. Thyroid 2002; 12:459.</a></li><li class="breakAll">Klein I, Biondi B. Endocrine disorders and cardiovascular disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Bonow RO, Mann DL, Tomaselli GF, Bhatt D (Eds), Saunders Elsevier, Philadelphia 2019. p.1807.</li><li><a class="nounderline abstract_t">Ventrella, S, Klein, I. Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. Endocrinologist 1994; 4:391.</a></li><li><a class="nounderline abstract_t">Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007; 116:1725.</a></li><li><a class="nounderline abstract_t">Ojamaa K, Klein I, Sabet A, Steinberg SF. Changes in adenylyl cyclase isoforms as a mechanism for thyroid hormone modulation of cardiac beta-adrenergic receptor responsiveness. Metabolism 2000; 49:275.</a></li><li><a class="nounderline abstract_t">Mintz G, Pizzarello R, Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. J Clin Endocrinol Metab 1991; 73:146.</a></li><li><a class="nounderline abstract_t">Osman F, Franklyn JA, Holder RL, et al. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. J Am Coll Cardiol 2007; 49:71.</a></li><li><a class="nounderline abstract_t">Iglesias P, Acosta M, Sánchez R, et al. Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 2005; 63:66.</a></li><li><a class="nounderline abstract_t">Kim HJ, Jo SH, Lee MH, et al. Hyperthyroidism Is Associated with the Development of Vasospastic Angina, but Not with Cardiovascular Outcomes. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993; 77:334.</a></li><li><a class="nounderline abstract_t">Dörr M, Wolff B, Robinson DM, et al. The association of thyroid function with cardiac mass and left ventricular hypertrophy. J Clin Endocrinol Metab 2005; 90:673.</a></li><li><a class="nounderline abstract_t">Dahl P, Danzi S, Klein I. Thyrotoxic cardiac disease. Curr Heart Fail Rep 2008; 5:170.</a></li><li><a class="nounderline abstract_t">Kellett HA, Sawers JS, Boulton FE, et al. Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med 1986; 58:43.</a></li><li><a class="nounderline abstract_t">Kurnik D, Loebstein R, Farfel Z, et al. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 2004; 83:107.</a></li><li><a class="nounderline abstract_t">Wustmann K, Kucera JP, Zanchi A, et al. Activation of electrical triggers of atrial fibrillation in hyperthyroidism. J Clin Endocrinol Metab 2008; 93:2104.</a></li><li><a class="nounderline abstract_t">Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 2004; 164:1675.</a></li><li><a class="nounderline abstract_t">Petersen P. Thromboembolic complications in atrial fibrillation. Stroke 1990; 21:4.</a></li><li><a class="nounderline abstract_t">Malik S, Russman AN, Katramados AM, et al. Moyamoya syndrome associated with Graves' disease: a case report and review of the literature. J Stroke Cerebrovasc Dis 2011; 20:528.</a></li><li><a class="nounderline abstract_t">Li D, Yang W, Xian P, et al. Coexistence of moyamoya and Graves' diseases: the clinical characteristics and treatment effects of 21 Chinese patients. Clin Neurol Neurosurg 2013; 115:1647.</a></li><li><a class="nounderline abstract_t">Siu CW, Yeung CY, Lau CP, et al. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart 2007; 93:483.</a></li><li><a class="nounderline abstract_t">Ismail HM. Reversible pulmonary hypertension and isolated right-sided heart failure associated with hyperthyroidism. J Gen Intern Med 2007; 22:148.</a></li><li><a class="nounderline abstract_t">Schultz M, Kistorp C, Langdahl B, et al. N-terminal-pro-B-type natriuretic peptide in acute hyperthyroidism. Thyroid 2007; 17:237.</a></li><li class="breakAll">Danzi S, Klein I. Treatment of hypertension and thyroid disease. In: Advanced Therapy in Hypertension and Vascular Disease, Mohler ER, Townsend RR (Eds), BC Decker Inc., Ontario, Canada 2006. p.354.</li><li><a class="nounderline abstract_t">Lozano HF, Sharma CN. Reversible pulmonary hypertension, tricuspid regurgitation and right-sided heart failure associated with hyperthyroidism: case report and review of the literature. Cardiol Rev 2004; 12:299.</a></li><li><a class="nounderline abstract_t">Mercé J, Ferrás S, Oltra C, et al. Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study. Am J Med 2005; 118:126.</a></li><li><a class="nounderline abstract_t">Siu CW, Zhang XH, Yung C, et al. Hemodynamic changes in hyperthyroidism-related pulmonary hypertension: a prospective echocardiographic study. J Clin Endocrinol Metab 2007; 92:1736.</a></li><li><a class="nounderline abstract_t">Peters A, Ehlers M, Blank B, et al. Excess triiodothyronine as a risk factor of coronary events. Arch Intern Med 2000; 160:1993.</a></li><li><a class="nounderline abstract_t">Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343.</a></li><li><a class="nounderline abstract_t">Clozel JP, Danchin N, Genton P, et al. Effects of propranolol and of verapamil on heart rate and blood pressure in hyperthyroidism. Clin Pharmacol Ther 1984; 36:64.</a></li><li><a class="nounderline abstract_t">Subahi A, Ibrahim W, Abugroun A. Diltiazem-Associated Cardiogenic Shock in Thyrotoxic Crisis. Am J Ther 2018; 25:e666.</a></li><li><a class="nounderline abstract_t">Featherstone HJ, Stewart DK. Angina in thyrotoxicosis. Thyroid-related coronary artery spasm. Arch Intern Med 1983; 143:554.</a></li></ol></div><div id="topicVersionRevision">Topic 7853 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172193" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Thyroid hormone and the cardiovascular system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8078532" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The molecular basis of thyroid hormone action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12165107" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nongenomic actions of thyroid hormone on the heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12165107" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Nongenomic actions of thyroid hormone on the heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17923583" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Thyroid disease and the heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10690958" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Changes in adenylyl cyclase isoforms as a mechanism for thyroid hormone modulation of cardiac beta-adrenergic receptor responsiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2045465" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17207725" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15963064" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32961722" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hyperthyroidism Is Associated with the Development of Vasospastic Angina, but Not with Cardiovascular Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8345037" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15522926" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The association of thyroid function with cardiac mass and left ventricular hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18752767" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Thyrotoxic cardiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3704105" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Problems of anticoagulation with warfarin in hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15028964" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18349059" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Activation of electrical triggers of atrial fibrillation in hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302638" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2405547" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Thromboembolic complications in atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21130668" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Moyamoya syndrome associated with Graves' disease: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23518423" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Coexistence of moyamoya and Graves' diseases: the clinical characteristics and treatment effects of 21 Chinese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005710" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17351857" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Reversible pulmonary hypertension and isolated right-sided heart failure associated with hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17381357" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : N-terminal-pro-B-type natriuretic peptide in acute hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17381357" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : N-terminal-pro-B-type natriuretic peptide in acute hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15476566" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Reversible pulmonary hypertension, tricuspid regurgitation and right-sided heart failure associated with hyperthyroidism: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15694895" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17327384" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hemodynamic changes in hyperthyroidism-related pulmonary hypertension: a prospective echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10888973" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Excess triiodothyronine as a risk factor of coronary events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27521067" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6734051" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effects of propranolol and of verapamil on heart rate and blood pressure in hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29521654" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Diltiazem-Associated Cardiogenic Shock in Thyrotoxic Crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6402998" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Angina in thyrotoxicosis. Thyroid-related coronary artery spasm.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
